Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

• Published in: Nature communications Vol. 12; no. 1; pp. 1967 - 10
• Main Authors: Jagannathan, Prasanna, Andrews, Jason R., Bonilla, Hector, Hedlin, Haley, Jacobson, Karen B., Balasubramanian, Vidhya, Purington, Natasha, Kamble, Savita, de Vries, Christiaan R., Quintero, Orlando, Feng, Kent, Ley, Catherine, Winslow, Dean, Newberry, Jennifer, Edwards, Karlie, Hislop, Colin, Choong, Ingrid, Maldonado, Yvonne, Glenn, Jeffrey, Bhatt, Ami, Blish, Catherine, Wang, Taia, Khosla, Chaitan, Pinsky, Benjamin A., Desai, Manisha, Parsonnet, Julie, Singh, Upinder
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2779/777; 692/699/255/2514; Adult; Aged; Antiviral Agents - administration & dosage; Confidence intervals; Coronaviruses; COVID-19; COVID-19 - drug therapy; COVID-19 - virology; Female; Humanities and Social Sciences; Humans; Injections, Subcutaneous; Interferon; Interleukins - administration & dosage; Male; Middle Aged; multidisciplinary; Outpatients; Placebos; Polyethylene Glycols - administration & dosage; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; Single-Blind Method; Transaminase; Treatment Failure; Viral diseases; Virus Shedding - drug effects; Young Adult
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-021-22177-1

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19. Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duration of SARS-CoV-2 viral shedding nor improves symptoms.